from Yahoo Board ********** Per 10Q - $39.3MM i
Post# of 148168
(Total Views: 748)
Posted On: 10/09/2020 6:12:44 PM
from Yahoo Board
**********
Per 10Q - $39.3MM increase in inventory
"The material factors considered by the Company in evaluating these uncertainties include the receipt and analysis of positive Phase 3 clinical trial results for the underlying product candidate".
"I noticed the 10-K mentioned " currently in the process of a full interim analysis of the first 195 patients enrolled".
"Typically, capitalization of such inventory begins when the results of clinical trials have reached a status sufficient to support regulatory approval..
**********
FDA Commissioner Gotlieb on TV and he was asked about Regeneron and Lilly mabs and he said that production is nowhere near to scale and even with all they could produce by the end of the year, it will have to be rationed to the most in need.
******
Google this peer review paper that’s just published: “Chemokine receptor gene polymorphisms and COVID-19: Could knowledge gained from HIV/AIDS be important” - “Following treatment with the CCR5-blocking antibody leronlimab, the authors observed complete CCR5 receptor occupancy on macrophage and T cells, rapid reduction of plasma IL-6, restoration of the CD4/CD8 ratio, and a significant decrease in SARS-CoV-2 plasma viremia.”
**********
Per 10Q - $39.3MM increase in inventory
"The material factors considered by the Company in evaluating these uncertainties include the receipt and analysis of positive Phase 3 clinical trial results for the underlying product candidate".
"I noticed the 10-K mentioned " currently in the process of a full interim analysis of the first 195 patients enrolled".
"Typically, capitalization of such inventory begins when the results of clinical trials have reached a status sufficient to support regulatory approval..
**********
FDA Commissioner Gotlieb on TV and he was asked about Regeneron and Lilly mabs and he said that production is nowhere near to scale and even with all they could produce by the end of the year, it will have to be rationed to the most in need.
******
Google this peer review paper that’s just published: “Chemokine receptor gene polymorphisms and COVID-19: Could knowledge gained from HIV/AIDS be important” - “Following treatment with the CCR5-blocking antibody leronlimab, the authors observed complete CCR5 receptor occupancy on macrophage and T cells, rapid reduction of plasma IL-6, restoration of the CD4/CD8 ratio, and a significant decrease in SARS-CoV-2 plasma viremia.”
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼